Antifungal agents: mechanisms of action

被引：856

作者：

Odds, FC ^{[1
]}

Brown, AJP ^{[1
]}

Gow, NAR ^{[1
]}

机构：

[1] Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen Fungal Grp, Aberdeen AB25 2ZD, Scotland

来源：

TRENDS IN MICROBIOLOGY | 2003年 / 11卷 / 06期

基金：

英国惠康基金; 英国生物技术与生命科学研究理事会;

关键词：

D O I：

10.1016/S0966-842X(03)00117-3

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Clinical needs for novel antifungal agents have altered steadily with the rise and fall of AIDS-related mycoses, and the change in spectrum of fatal disseminated fungal infections that has accompanied changes in therapeutic immunosuppressive therapies. The search for new molecular targets for antifungals has generated considerable research using modern genomic approaches, so far without generating new agents for clinical use. Meanwhile, six new antifungal agents have just reached, or are approaching, the clinic. Three are new triazoles, with extremely broad antifungal spectra, and three are echinocandins, which inhibit synthesis of fungal cell wall polysaccharides - a new mode of action. In addition, the sordarins represent a novel class of agents that inhibit fungal protein synthesis. This review describes the targets and mechanisms of action of all classes of antifungal agents in clinical use or with clinical potential.

引用

页码：272 / 279

页数：8

共 31 条

[1]

BRAJTBURG JK, 1974, ANTIMICROB AGENTS CH, V5, P377

[2]

De Backer Marianne D, 2002, Am J Pharmacogenomics, V2, P113, DOI 10.2165/00129785-200202020-00004

[3] Sequencing the Aspergillus fumigatus genome [J].